SCHEMBL6740216

SCHEMBL6740216

Clc1ccccc1CCc1ccccc1Cl

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.71
IDO1 P14902 3/20 0.62
PNMT P11086 1/20 0.62
SLC6A2 P23975 1/20 0.58
SLC6A4 P31645 1/20 0.58
SLC6A3 Q01959 1/20 0.58
AOC3 Q16853 1/20 0.58
KCNH2 Q12809 1/20 0.58
HTR3E A5X5Y0 1/20 0.56
HTR3B O95264 1/20 0.56
HTR3A P46098 1/20 0.56
HTR3D Q70Z44 1/20 0.56
HTR3C Q8WXA8 1/20 0.56
DAO P14920 2/20 0.53
LMNA P02545 1/20 0.53
TSHR P16473 1/20 0.53
KMT2A Q03164 1/20 0.50
PKM P14618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10537178 0.87 TAAR1 (0.58) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL1822278 0.86 TAAR1 (0.62) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL575128 0.86 TAAR1 (0.62) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL20861010 0.85 TAAR1 (0.56) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL8706198 0.85 TAAR1 (0.56) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL838926 0.84 TAAR1 (0.60) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL320795 0.84 TAAR1 (0.60) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL266281 0.84 TAAR1 (1.00) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL1674574 0.84 TAAR1 (0.60) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL7432386 0.84 TAAR1 (0.60) TAAR1IDO1PNMTSLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559466-B2 Process for preparation of intermediates UPL LTD (IN) 2026-02-24 US claimed
EP-4385329-A2 IMPROVED PROCESS FOR PREPARATION OF INTERMEDIATES UPL Ltd (IN) 2024-06-19 EP claimed
CN-112399967-A Improved process for the preparation of intermediates UPL有限公司 2021-02-23 CN claimed
EP-3762356-A1 IMPROVED PROCESS FOR PREPARATION OF INTERMEDIATES UPL Ltd (IN) 2021-01-13 EP claimed
US-20200399236-A1 IMPROVED PROCESS FOR PREPARATION OF INTERMEDIATES UPL LTD (IN) 2020-12-24 US claimed
WO-2019171161-A1 IMPROVED PROCESS FOR PREPARATION OF INTERMEDIATES UPL LTD (IN) 2019-09-12 WO claimed
US-12559466-B2 Process for preparation of intermediates UPL LTD (IN) 2026-02-24 US disclosed
EP-4385329-A2 IMPROVED PROCESS FOR PREPARATION OF INTERMEDIATES UPL Ltd (IN) 2024-06-19 EP disclosed
US-11129827-B2 Dual MAGL and FAAH inhibitors ABIDE THERAPEUTICS, INC. (US) 2021-09-28 US disclosed
CN-112399967-A Improved process for the preparation of intermediates UPL有限公司 2021-02-23 CN disclosed
US-20200399236-A1 IMPROVED PROCESS FOR PREPARATION OF INTERMEDIATES UPL LTD (IN) 2020-12-24 US disclosed
US-20200399236-A1 IMPROVED PROCESS FOR PREPARATION OF INTERMEDIATES UPL LTD (IN) 2020-12-24 US disclosed
US-20190282568-A1 DUAL MAGL AND FAAH INHIBITORS LUNDBECK LA JOLLA RESEARCH CENTER, INC. 2019-09-19 US disclosed
US-6686428-B2 TRANSMETALLATION REAGENTS REACTED WITH ALPHA-HALOCARBONYL COMPOUNDS IN THE PRESENCE OF A METAL CATALYST THE PENN STATE RESEARCH FOUNDATION 2004-02-03 US disclosed
US-20020193543-A1 Transmetallation reagents reacted with alpha-halocarbonyl compounds in the presence of a metal catalyst NATIONAL INSTITUTES OF HEALTH 2002-12-19 US disclosed
EP-0415247-B1 Process for the preparation of ether solutions of arylmethylmagnesium halides BASF AG (DE) 1995-10-25 EP disclosed
US-5093046-A Suppression of dimerization BASF AKTIENGESELLSCHAFT (DE) 1992-03-03 US disclosed
EP-0415247-A2 Process for the preparation of ether solutions of arylmethylmagnesium halides BASF Aktiengesellschaft (DE) 1991-03-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559466-B2 Process for preparation of intermediates CBR1, POR, CYP2E1 TAAR1 500/4885IDO1 321/4885PNMT 445/4885
US-11129827-B2 Dual MAGL and FAAH inhibitors FAAH, FAAH2, MAG TAAR1 284/4885IDO1 1230/4885PNMT 578/4885
US-20200399236-A1 IMPROVED PROCESS FOR PREPARATION OF INTERMEDIATES OGDH, OXGR1, POR TAAR1 721/4885IDO1 528/4885PNMT 465/4885
US-20190282568-A1 DUAL MAGL AND FAAH INHIBITORS FAAH, FAAH2, MAG TAAR1 284/4885IDO1 1230/4885PNMT 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.